- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
- NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
- NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
- NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
- NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
- NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
- NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
More ▼
Key statistics
On Thursday, Neuropace Inc (NPCE:NMQ) closed at 13.90, -23.42% below its 52-week high of 18.15, set on Feb 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.01 |
---|---|
High | 14.08 |
Low | 13.70 |
Bid | 13.49 |
Offer | 16.35 |
Previous close | 13.97 |
Average volume | 99.57k |
---|---|
Shares outstanding | 28.72m |
Free float | 23.12m |
P/E (TTM) | -- |
Market cap | 401.22m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼